Загрузка...

Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-yea...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Endocrinol (Lausanne)
Главные авторы: Syro, Luis V., Rotondo, Fabio, Camargo, Mauricio, Ortiz, Leon D., Serna, Carlos A., Kovacs, Kalman
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2018
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6013558/
https://ncbi.nlm.nih.gov/pubmed/29963012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00318
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!